In This Article:
As global markets navigate through mixed economic signals, Sweden's market remains a focal point for investors looking for growth opportunities. This context sets the stage to explore three Swedish growth companies with high insider ownership, which often indicates confidence from those closest to the company's operations and future prospects.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 21.6% |
| BioArctic (OM:BIOA B) | 35.1% | 50.5% |
| Sileon (OM:SILEON) | 33.3% | 109.3% |
| KebNi (OM:KEBNI B) | 37.8% | 90.4% |
| InCoax Networks (OM:INCOAX) | 17.9% | 104.9% |
| Calliditas Therapeutics (OM:CALTX) | 10.5% | 52.9% |
| Egetis Therapeutics (OM:EGTX) | 17.6% | 98.2% |
| edyoutec (NGM:EDYOU) | 14.6% | 63.1% |
| Yubico (OM:YUBICO) | 37.5% | 43.4% |
| SaveLend Group (OM:YIELD) | 24.9% | 103.4% |
Let's review some notable picks from our screened stocks.
Attendo
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Attendo AB (publ) operates in the provision of health and care services across Scandinavia and Finland, with a market capitalization of approximately SEK 6.94 billion.
Operations: The company generates SEK 17.63 billion from its Care and Health Care Services segment.
Insider Ownership: 15%
Attendo is poised for notable growth with earnings forecasted to increase by 21.8% annually, outpacing the Swedish market's 14.3%. Despite a low return on equity projection of 9.3% in three years, its price-to-earnings ratio at 17.1x remains attractive compared to the Swedish average of 23.3x. Recent insider activities show more buying than selling, although not in substantial volumes, indicating moderate confidence among insiders. The company also actively engages in share repurchases to optimize capital usage and potentially enhance shareholder value.
Egetis Therapeutics
Simply Wall St Growth Rating: ★★★★★★
Overview: Egetis Therapeutics AB is a Swedish pharmaceutical company specializing in late-stage development projects aimed at treating serious diseases within the orphan drug segment, with a market capitalization of approximately SEK 2.65 billion.
Operations: The company generates revenue primarily from its Emcitate segment, which brought in SEK 62.90 million.
Insider Ownership: 17.6%
Egetis Therapeutics is expected to shift from unprofitable to profitable within three years, with anticipated earnings growth of 98.18% per year and revenue growth significantly outpacing the Swedish market at 73.6% annually. Despite trading at a substantial discount to its estimated fair value, shareholder dilution occurred over the past year. Recently, Egetis received a Promising Innovative Medicine designation in the UK for Emcitate®, enhancing its growth prospects amidst ongoing financial challenges indicated by a short cash runway.